A Phase IIb expansion trial of savolitinib in combination with Tagrisso® in Non Small Cell Lung Cancer patients.

Trial Profile

A Phase IIb expansion trial of savolitinib in combination with Tagrisso® in Non Small Cell Lung Cancer patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2016 New trial record
    • 02 Aug 2016 According to a Chi-Med media release, company expects to complete this Phase IIb expansion study by the end of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top